New York, NY (Press Release) – SELLAS Life Sciences Group, Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the devel­op­ment of novel cancer immuno­therapies for a broad range of cancer indi­ca­tions, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has approved orphan medicinal prod­uct desig­na­tion (OMPD) for galinpepimut‑S (GPS), the Company’s lead prod­uct can­di­date, for the treat­ment of multiple myeloma (MM). GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present …

New York, NY (Press Release) – SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS” or the “Company”), a clin­i­cal-stage bio­pharma­ceu­tical com­pany focused on the devel­op­ment of novel cancer immuno­therapies for a broad range of cancer indi­ca­tions, today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted Fast Track desig­na­tion to the Company’s lead asset, galin­pepimut-S (GPS), for the treat­ment of multiple myeloma (MM). GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.

The Company reported …

New York, NY (Press Release) – SELLAS Life Sciences Group Inc. (Nasdaq:SLS) (“SELLAS”), a clin­i­cal-stage bio­pharma­ceutical com­pany focused on novel cancer immuno­therapies for a broad range of cancer indi­ca­tions, today announced that the U.S. Food and Drug Admin­istra­tion (FDA) has granted orphan drug desig­na­tion to its novel drug can­di­date, galin­pepimut-S (GPS), for the treat­ment of multiple myeloma (MM). GPS is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms Tumor 1 (WT1) protein, which is present in an array of tumor types.

“We are delighted to receive this orphan drug …

Data Indicates Meaningful Clinical Benefit in High-risk Multiple Myeloma Patients

Zug, Switzerland and New York, NY (Press Release) – SELLAS Life Sciences Group (SELLAS or the Com­pany), a late-stage bio­pharma­ceutical com­pany focused on the devel­op­ment of novel cancer immuno­ther­a­pies and thera­peutics for a broad range of cancer indi­ca­tions, today reported positive results from the Company's phase II study of its WT1 first-in-class immuno­thera­peutic anti-cancer treat­ment in multiple myeloma (MM) patients fol­low­ing au­tol­o­gous stem cell trans­plan­ta­tion (ASCT). Initial results indicate for the first time a meaningful clin­i­cal benefit among high-risk multiple myeloma patients, …

• Recent Previous Reports Showed Positive Findings for WT1 Cancer Vaccine in Mesothelioma and Acute Myeloid Leukemia (AML) Patients
• SELLAS to Present at the Annual JP Morgan Healthcare Conference on January 12th at 3:30pm PST

Zug, Switzerland, and New York (Press Release) – SELLAS Life Sciences Group (SELLAS), a devel­op­ment-stage bio­pharma­ceu­tical com­pany focused on inno­va­tive prod­ucts to treat cancers and central nervous system (CNS) diseases, today reported positive results from the Company's Phase 1/2 clin­i­cal study of its WT1 cancer vaccine in patients with multiple …